Updates

Scapa - Moves to 24/7 shift working on healthcare side

July 2014

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Excellent results from Scapa. Sales went up 8% to Â£226.1m but pretax profit before exceptionals was up 17% to Â£14.9m. Eps were up 30% to 6.9p.The success driver was again Healthcare, which grew its sales and profit before central costs by 21% to Â£69.2m and Â£10.2m respectively. Margins went to a record 14.7% (compare to the margins in Advanced Medical Solutions -page 6). Scapa says that most of the growth is coming from outsourced contracts with blue chip customers and growing demand from existing products and new product launches, predominantly around skin friendly turn-key products resulting in it overtrading and moving to 24/7 production. In terms of â€œoldâ€ Scapa, the industrial tapes side pe ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Pressure Technologies - 18% upgrade to forecasts

CML

Scapa - Factories "essential business" status (April 2020)

Scapa (December 2018)

Scapa (November 2017)

Scapa - Now a 10-bagger since 2011 (July 2017)

Scapa (November 2016)

Scapa - Debt down massively (May 2016)

Scapa (January 2016)

Scapa (November 2015)

Scapa (June 2015)

Scapa - Third profit upgrade since November (May 2015)

Scapa - £11.3m healthcare acquisition (April 2015)

Scapa - Healthcare side margins rocket (January 2014)

Scapa - Talks with Tapex (Korea) may resume (July 2013)

Scapa (December 2012)

Scapa (November 2012)

Scapa - Going to beat market forecasts (May 2012)

Scapa - Buys US adhesive-backed woundcare manufacturer (March 2012)

Scapa - New markets in medical and electronic tapes look good (November 2011)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X